Cyclophosphamide (CTX) and high-dose 4-Epidoxorubicin (EPI) in advanced ovarian cancer (OC) treatment

Cancer of the ovary is the fifth cause of cancer death in women, and the majority of patients have advanced stage disease at the time of presentation [1]. Clinical responses can be achieve with current regimens in over half of patients but only a minority enjoy prolonged disease free survival [2]. Consequently there is a need for innovative strategies to improve the prognosis in advanced stage patients. We have treated 52 consecutive patients, since September ‘87, with advanced ovarian cancer, utilizing a combination regimen based on the association between CTX and high-dose EPI-ADM in delayed administration.